Alnylam Pharmaceuticals | ALNY - Current Liabilities


Alnylam Pharmaceuticals reported $1.51B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Takeda JPY 2.76T 335.02B Jun/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026
Xencor USD 81.86M 8.41M Jun/2026